Shaperon registers patent in Australia for ‘Nugel’ composition, a candidate substance for atopic dermatitis treatment

[by Ji, Yong Jun] Shaperon announced on November 21 that it has secured a patent in Australia for the core composition of its atopic dermatitis treatment candidate, ‘NuGel.’

With the issuance of this patent, the company has secured long-term exclusivity for NuGel, extending the patent protection period until 2042.

The patent covers a gel formulation technology containing the GPCR19 agonist ‘HY209,’ hyaluronic acid, and polysorbate. This formulation technology is incorporated into NuGel, which is currently in Phase 2 clinical development in the United States. The Phase 2 Part 2 trial of NuGel is currently in progress, following the completion of Part 1.

According to the company, NuGel provides a differentiated competitive advantage over conventional topical steroids and immunosuppressants, and it has shown markedly reduced side effects and superior therapeutic efficacy in patients with mild to moderate atopic dermatitis who require long-term management.

Shaperon's strategy is to secure ample patent protection for future technology export and commercialization discussions by expanding patent applications in major global markets, including the United States, Korea, Europe, Japan, China, and Canada, beginning with the Australian patent. The company further noted that the newly granted patent will not only secure exclusive market access in Australia, but will also serve as a key asset in global technology transfer negotiations by demonstrating strong commercial viability.

The global atopic dermatitis treatment market is valued at approximately USD 16.8 billion (approximately KRW 24 trillion) this year and is projected to grow to USD 50.8 billion by 2035. The Australian market is likewise expected to record substantial growth, rising from USD 553.8 million last year to USD 1.0554 billion by 2030.

By patient segment, current biologic therapies for atopic dermatitis are largely prescribed for patients with moderate to severe disease (30-45% of all patients), generating USD 14.9 billion (KRW 21 trillion) in annual sales last year. In contrast, the vast majority of patients, an estimated 55-70% with mild to moderate disease, tend to prefer topical formulations such as gels, creams, and lotions. Reflecting these characteristics, topical treatments account for more than 45% of the overall market, whereas biologics represent only 26%.

"NuGel is expected to address the limitations of existing biologic therapies and provide a practical therapeutic option for patients with mild to moderate disease requiring long-term management. Leveraging our clinical data and patent portfolio, we plan to actively advance global commercialization and pursue technology out-licensing opportunities," a Shaperon official said.